Trilotab is a chewable, chicken-flavoured tablet formulated to manage both PDH and ADH forms of Cushing's syndrome in dogs. The active ingredient, trilostane, functions by selectively and reversibly inhibiting the enzyme 3β-hydroxysteroid dehydrogenase. This inhibition disrupts the synthesis of cortisol, corticosterone, and aldosterone, thereby reducing the excessive cortisol levels characteristic of Cushing's syndrome.
Cushing's syndrome, or hyperadrenocorticism, is a prevalent endocrine disorder in dogs, particularly affecting those in middle to older age brackets. The condition arises from prolonged exposure to elevated cortisol levels, a hormone produced by the adrenal glands. Cortisol plays a vital role in regulating metabolism, immune response, and stress. However, excessive amounts can lead to various health issues.
There are two primary forms of Cushing's syndrome in dogs:
-
Pituitary-Dependent Hyperadrenocorticism (PDH): This...
Trilotab is a chewable, chicken-flavoured tablet formulated to manage both PDH and ADH forms of Cushing's syndrome in dogs. The active ingredient, trilostane, functions by selectively and reversibly inhibiting the enzyme 3β-hydroxysteroid dehydrogenase. This inhibition disrupts the synthesis of cortisol, corticosterone, and aldosterone, thereby reducing the excessive cortisol levels characteristic of Cushing's syndrome.
Cushing's syndrome, or hyperadrenocorticism, is a prevalent endocrine disorder in dogs, particularly affecting those in middle to older age brackets. The condition arises from prolonged exposure to elevated cortisol levels, a hormone produced by the adrenal glands. Cortisol plays a vital role in regulating metabolism, immune response, and stress. However, excessive amounts can lead to various health issues.
There are two primary forms of Cushing's syndrome in dogs:
-
Pituitary-Dependent Hyperadrenocorticism (PDH): This form accounts for approximately 85% of cases and is caused by a benign tumour in the pituitary gland, leading to overstimulation of the adrenal glands and excessive cortisol production.
-
Adrenal-Dependent Hyperadrenocorticism (ADH): Representing about 15% of cases, this form results from a tumour in one or both adrenal glands, directly increasing cortisol secretion.
Common clinical signs of Cushing's syndrome include increased thirst and urination, heightened appetite, abdominal enlargement (often referred to as a "pot-bellied" appearance), hair loss, thinning skin, and muscle weakness. Due to the gradual onset and non-specific nature of these symptoms, diagnosing Cushing's syndrome can be challenging and often requires comprehensive veterinary assessment.
Key Features of Trilotab
-
Chewable and Flavoured: The tablets are designed to be palatable, with a chicken flavour to facilitate easy administration. Notably, they utilise hydrolysed chicken flavouring, making them suitable for dogs with chicken allergies.
-
Divisible Tablets: Each tablet is scored, allowing it to be divided into halves or quarters. This feature enables precise dosing tailored to the individual dog's weight and response to treatment, ensuring effective management of the condition.
-
Flexible Dosage Forms: Trilotab is available in 10 mg, 30 mg, and 60 mg strengths, supporting accurate dosing and potentially reducing the need for multiple tablet strengths in practice.
Administration and Dosage
The recommended starting dose of Trilotab is 2 mg of trilostane per kilogram of the dog's body weight, administered once daily with food. Morning administration is advised to facilitate monitoring tests 4 to 6 hours post-dosing. Regular monitoring of the dog's clinical signs and hormone levels is essential to adjust the dose to the minimum effective amount that controls the disease's manifestations.
Monitoring and Adjustments
Individual responses to trilostane can vary; therefore, consistent veterinary evaluations are crucial. Adjustments to the dosage may be necessary based on clinical assessments and laboratory results to maintain optimal control over cortisol levels and associated symptoms.
Benefits of Trilotab
-
Improved Compliance: The chewable, flavoured formulation enhances palatability, which can lead to better acceptance by dogs and ease of administration for pet owners.
-
Precise Dosing: The divisible nature of the tablets allows for accurate dose adjustments, ensuring each dog receives the appropriate amount of medication tailored to their specific needs.
-
Simplified Stock Management: With three available strengths, veterinary practices can effectively manage their inventory while providing precise dosing options for various dog sizes and requirements.
Safety and Precautions
Trilotab is generally well-tolerated; however, potential side effects may include gastrointestinal disturbances such as vomiting or diarrhoea, lethargy, and loss of appetite. In rare instances, more severe reactions can occur. It is imperative to adhere to the prescribed dosing regimen and maintain regular veterinary check-ups to monitor the dog's response to treatment and adjust the dosage as necessary.
Managing Cushing's syndrome in dogs requires a comprehensive approach, including accurate diagnosis, appropriate medication, and ongoing monitoring. Trilotab offers a practical solution with its palatable, divisible tablets, facilitating precise dosing and potentially improving the quality of life for affected dogs. Consultation with a veterinarian is essential to determine the suitability of Trilotab for individual cases and to establish a tailored treatment plan.
